AKR1C3 Human
Escherichia Coli.
DD3, DDX, HAKRB, HAKRe, HA1753, HSD17B5, hluPGFS, KIAA0119, AKR1C3, Aldo-keto reductase family 1 member C3, 3-alpha-HSD type 2, 17-beta-HSD 5, PGFS, DD-3.
Greater than 90.0% as determined by SDS-PAGE.
Description
AKR1C3 Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 323 amino acids (1-323) and having a molecular mass of 36.8 kDa.
AKR1C3 is purified by proprietary chromatographic techniques.
Product Specs
Aldo-keto reductase family 1 member C3 isoform 1 (AKR1C3) is an enzyme belonging to the aldo-keto reductase family. It facilitates the conversion of ketones and aldehydes to their corresponding alcohol forms using cofactors like NADPH and NADH. AKR1C3 plays a role in reducing prostaglandin (PG), phenanthrenequinone (PQ), and PGH2. Additionally, it is involved in oxidizing 9 alpha, 11 beta-PGF2 to PGD2. AKR1C3 is considered important in the development of allergic conditions such as asthma and might also contribute to the regulation of cell growth and differentiation.
Recombinant human AKR1C3, produced in E. coli, is a single, non-glycosylated polypeptide chain comprising 323 amino acids (1-323) with a molecular weight of 36.8 kDa.
The protein undergoes purification using proprietary chromatographic methods.
The AKR1C3 solution is supplied at a concentration of 1mg/ml and contains 10% glycerol, 0.1M NaCl, 1mM DTT, and 20mM Tris-HCl buffer at pH 8.5.
Adding a carrier protein such as HSA or BSA (0.1%) is advisable for long-term storage.
Repeated freeze-thaw cycles should be avoided.
The purity of the product is determined to be greater than 90.0% based on SDS-PAGE analysis.
The specific activity of the enzyme is greater than 1,000 pmol/min/µg, which is defined as the amount of enzyme required to catalyze the oxidation of 1.0 pmole of 1-Acenaphthenol per minute in the presence of NADP at pH 8.8 and a temperature of 25°C.
DD3, DDX, HAKRB, HAKRe, HA1753, HSD17B5, hluPGFS, KIAA0119, AKR1C3, Aldo-keto reductase family 1 member C3, 3-alpha-HSD type 2, 17-beta-HSD 5, PGFS, DD-3.
Escherichia Coli.
MDSKHQCVKL NDGHFMPVLG FGTYAPPEVP RSKALEVTKL AIEAGFRHID SAHLYNNEEQ VGLAIRSKIA DGSVKREDIF YTSKLWSTFH RPELVRPALE NSLKKAQLDY VDLYLIHSPM SLKPGEELSP TDENGKVIFD IVDLCTTWEA MEKCKDAGLA KSIGVSNFNR RQLEMILNKP GLKYKPVCNQ VECHPYFNRS KLLDFCKSKD IVLVAYSALG SQRDKRWVDP NSPVLLEDPV
LCALAKKHKR TPALIALRYQ LQRGVVVLAK SYNEQRIRQN VQVFEFQLTA EDMKAIDGLD RNLHYFNSDS FASHPNYPYS DEY
Product Science Overview
The AKR1C3 gene is located on chromosome 10p15-p14 and shares high sequence identity with three other gene members clustered in the same region . The gene encodes a protein that is involved in the reduction of prostaglandin D2, prostaglandin H2, and phenanthrenequinone, as well as the oxidation of prostaglandin F2α to prostaglandin D2 . The enzyme is also capable of metabolizing estrogen and progesterone .
AKR1C3 plays a crucial role in steroid metabolism. It catalyzes oxidation/reduction reactions at the 3-alpha, 20-alpha, and 17-beta positions of steroids . This enzyme is involved in the conversion of adrenal androgens, such as dehydroepiandrosterone and androstenedione, into androstenediol and testosterone . Additionally, AKR1C3 is known as Prostaglandin F Synthase because it reduces prostaglandin D2 to F2, which may play a role in allergic conditions such as asthma .
AKR1C3 is overexpressed in prostate cancer and is associated with the development of castration-resistant prostate cancer (CRPC) . Its overexpression may serve as a promising biomarker for prostate cancer progression . Furthermore, AKR1C3 may play an important role in the pathogenesis of allergic diseases such as asthma and may also have a role in controlling cell growth and/or differentiation .
Recombinant human AKR1C3 is produced using recombinant DNA technology, which involves inserting the human AKR1C3 gene into a suitable expression system, such as bacteria or yeast, to produce the protein in large quantities. This recombinant protein is used in various research applications to study its function, structure, and role in disease processes.
